Related Experiment Video
Updated: Mar 6, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Patient and Caregiver Preferences for Once-Weekly Injection Devices for the Treatment of Growth Hormone Deficiency
Jing Voon Chen1, Bradley S Miller2,3, Nicky Kelepouris4
1Health Economics and Outcomes Research, Novo Nordisk Inc, Plainsboro, NJ 08536, USA.
Context:
Once-weekly long-acting growth hormone (GH) analogue (LA-GHA) treatments offer an alternative to once-daily GH injections for the treatment of children and adults with GH deficiency (GHD). With these new LA-GHA options, it is important to understand patients' and caregivers' treatment preferences.
Objective:
This work aimed to understand the injection/device attributes important to patients with GHD and caregivers when choosing LA-GHA treatment options.
Methods:
In this cross-sectional study, a targeted literature review and qualitative interviews informed the development of an online survey. The survey included a discrete choice experiment, comprising a series of choice tasks. Respondents selected between hypothetical, experimentally designed, once-weekly LA-GHA device features corresponding to currently available devices. Study participants were patients/caregivers in the United States, self-reporting a GHD diagnosis and current short-acting GH injection use: adults (aged ≥18 years), caregivers of children (aged 3-11 years), and dyads of adolescents (aged 12-17 years) and their caregivers.
Results:
In total, 100 participants completed the survey: 50 adults, 25 caregivers, and 25 adolescent/caregiver dyads. Overall, the most important LA-GHA attributes identified were postinjection pain (27%), the number of injections needed for 1 full dose (23%), and the time needed to prepare the device before each injection (16%). The profile similar to somapacitan-beco had the highest predicted choice probability (82%) compared with the profiles similar to lonapegsomatropin-tcgd (16%) and somatrogon-ghla (2%).
Conclusion:
Understanding patient and caregiver preferences for LA-GHA devices with less injection pain and greater ease of use highlights the value of shared decision-making, potentially leading to better treatment adherence and subsequent clinical outcomes.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Drug Dosing: Obese Patients
Modified-Release Drug Delivery Systems: Rate-Programmed I

